Annals of Surgical Oncology

, Volume 19, Issue 10, pp 3199–3204 | Cite as

Gender Differences in Breast Cancer: Analysis of 13,000 Breast Cancers in Men from the National Cancer Data Base

  • Jon M. Greif
  • Christopher M. Pezzi
  • V. Suzanne Klimberg
  • Lisa Bailey
  • Marlene Zuraek
Breast Oncology

Abstract

Purpose

To examine gender-specific differences in breast cancer utilizing the National Cancer Data Base (NCDB).

Methods

Breast cancer patients entered in the NCDB from 1998 through 2007 were compared by gender for demographics, tumor characteristics, treatment, and outcomes.

Results

A total of 13,457 men were compared to 1,439,866 women. Men were older, more often African American, less often Hispanic, had larger tumors, less often had low-grade disease, less often had stage 0 or I disease, and were more likely to have metastases to lymph nodes and/or distantly. Cancers in men were less likely lobular and more likely estrogen receptor and/or progesterone receptor positive. Men were more likely to have total mastectomy and less likely to receive radiotherapy. There was no difference in chemotherapy and little difference in hormone therapy rates. Differences in overall survival (OS) were highly significant (p < 0.0001): 83 % 5-year OS for women with breast cancer (median survival 129 months) versus 74 % for men (median survival 101 months). Women had better 5-year OS (p < 0.0001) for stage 0 (94 vs. 90 %), stage I (90 vs. 87 %), and stage II (82 vs. 74 %) breast cancer. There were no differences in 5-year OS for stage III (56.9 vs. 56.5 %, p = 0.99) or stage IV (19 vs. 16 %, p = 0.20) disease.

Conclusions

At first glance, this large study demonstrated numerous gender-specific differences. However, after accounting for differences in presentation, absence of data on disease-specific survival, and inherent deficiencies in reporting cancer registry data, breast cancer in men and women appears more alike than different.

Keywords

Breast Cancer Overall Survival National Cancer Data Base Receive Hormone Therapy Lobular Histology 

Notes

Conflict of interest

The authors have no conflicts or other disclosures.

References

  1. 1.
    Miao H, Verkooljen HM, Chia K, et al. Incidence and outcome of male breast cancer: an international population-based study. J Clin Oncol. 2011;29:4381–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Scott-Connor CEH, Jochimsen PR, Menck HR, Winchester DJ. An analysis of male and female breast cancer treatment and survival among demographically identical pairs of patients. Surgery. 1999;126:775–81.CrossRefGoogle Scholar
  3. 3.
    National Cancer Data Base. http://www.facs.org/cancer/ncdb/index.html.
  4. 4.
    Commission on Cancer. http://www.facs.org/cancer/.
  5. 5.
    American College of Surgeons. http://www.facs.org/.
  6. 6.
    American cancer society. http://www.cancer.org/.
  7. 7.
    NCDB Alpha participant use file (NCDB alpha-PUF). http://www.facs.org/cancer/ncdb/pufgettingstarted.pdf.
  8. 8.
  9. 9.
    American Joint Committee on Cancer. http://www.cancerstaging.org/.
  10. 10.
    Health Insurance Portability and Accountability Act (HIPAA) rules and regulations. http://www.hhs.gov/ocr/privacy/hipaa/administrative/privacyrule/adminsimpregtext.pdf.
  11. 11.
    Weaver DL, Ashikaga T, Krag DN, et al. Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med. 2011;364:412–21.PubMedCrossRefGoogle Scholar
  12. 12.
    Kiluk JV, Lee MC, Park CK, et al. Male breast cancer: management and follow-up recommendations. Breast J. 2011;17:503–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Surveillance, epidemiology and end results (SEER). http://seer.cancer.gov/.
  14. 14.
    Mettlin CJ, Menck HR, Winchester DP, Murphy GP. A comparison of breast, colorectal, lung, and prostate cancers reported to the National Cancer Data Base and the Surveillance, Epidemiology, and End Results Program. Cancer. 1997;79:2052–61.PubMedCrossRefGoogle Scholar
  15. 15.
    O’Malley CD, Prehn AW, Shema SJ, Glaser SL. Racial/ethnic differences in survival rates in a population-based series of men with breast carcinoma. Cancer. 2002;94:2836–43.PubMedCrossRefGoogle Scholar
  16. 16.
    Giordano SH, Cohen DS, Buzdar AU, et al. Breast carcinoma in men: a population-based study. Cancer. 2004;101:51–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Nahleh ZA, Srikantiah R, Safa M, Jazieh AR, Muhleman A, Komrokji R. Male breast cancer in the veterans affairs population: a comparative analysis. Cancer. 2007;109:1471–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Acs G, Lawton TJ, Rebbeck TR, LiVolsi VA, Zhang PJ. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Pathol. 2001;115:85–98.PubMedCrossRefGoogle Scholar
  19. 19.
    Cancer Programs Practice Profile Reports (CP3R), version 2. http://www.facs.org/cancer/ncdb/cp3rv2_overview-1211.pdf.
  20. 20.
    Rapid Quality Reporting System (RQRS). http://www.facs.org/cancer/ncdb/rqrs.html.
  21. 21.
    National Comprehensive Cancer Network (NCCN). http://www.nccn.org/index.asp.
  22. 22.
    Gamel JW, Vogel RL. Non-parametric comparison of relative versus cause-specific survival in surveillance, epidemiology and end results (SEER) programme breast cancer patients. Stat Methods Med Res. 2001;10:393–52.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2012

Authors and Affiliations

  • Jon M. Greif
    • 1
    • 2
    • 6
  • Christopher M. Pezzi
    • 3
  • V. Suzanne Klimberg
    • 4
  • Lisa Bailey
    • 1
    • 2
  • Marlene Zuraek
    • 5
  1. 1.Carol Ann Read Breast Health CenterOaklandUSA
  2. 2.Alta Bates Summit Medical CenterOaklandUSA
  3. 3.Abington Memorial HospitalAbingtonUSA
  4. 4.University of Arkansas for Medical SciencesLittle RockUSA
  5. 5.Stanford University School of MedicinePalo AltoUSA
  6. 6.Bay Area Breast Surgeons, IncOaklandUSA

Personalised recommendations